ArticleAnnals of medicine and surgery (2012)2026
High-altitude pulmonary edema: a case series of four patients from Nepal.
Article in Annals of medicine and surgery (2012), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and importance: High-altitude pulmonary edema (HAPE) is a potentially fatal, non-cardiogenic pulmonary edema that develops after rapid ascent above 2500 m. Its incidence is influenced by ascent rate, altitude, and individual susceptibility, with risk factors including overexertion, cold exposure, respiratory infection, and genetic predisposition. Despite Nepal's extensive high-altitude trekking activity, published HAPE reports remain limited. This case series describes the clinical presentation, diagnostic features, and management outcomes of HAPE in Nepalese trekkers to promote early recognition and guide timely interventions. Methods: This retrospective case series included patients with HAPE managed at a tertiary care center in Nepal. Cases were identified from hospital records, and relevant literature was narratively reviewed to contextualize findings. Case presentation: Four previously healthy adults developed acute HAPE after rapid ascent above 4000 m in Nepal. They presented with dyspnea, cough, hypoxemia (SpO Clinical discussion: This series highlights the clinical variability of HAPE and emphasizes early diagnosis, descent, and oxygen therapy as mainstays of treatment. Rapid ascent, excessive exertion, cold exposure, and preceding respiratory infection were identified as common triggers. Diagnosis relied on clinical assessment supported by imaging, including bedside ultrasound. All patients recovered with conservative management. Conclusion: HAPE is life-threatening but reversible with prompt recognition and management. Strengthening clinician awareness, training, and early diagnostic capacity in high-altitude regions is essential to reduce associated morbidity and mortality.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.